Advanced searches left 3/3

Allergic Rhinitis - Crossref

Summarized by Plex Scholar
Last Updated: 04 August 2022

* If you want to update the article please login/register

Increased miR-124-3p alleviates type 2 inflammatory response in allergic rhinitis via IL-4Rα

However, the effect of miR-124-3p on type 2 inflammation in allergic rhinitis is uncertain. In AR, we wanted to investigate miR-124-3p's immune response and the mechanisms involved. Splenic lymphocytes from mice and peripheral blood mononuclear cells from healthy individuals were cultured and treated with miR-124-3p mimic/inhibitor. The allergic responses were based on a number of sneezing and nasal scratching, serum HDM-specific IgE levels, and the degree of nasal mucosa eosinophil infiltration. In both mouse splenic lymphocytes and human PBMCs in vitro, the miR-124-3p inhibitor reduced the IL-4Ru03b1, p-STAT6, IL-4, IL-5, and IL-13 expression levels, which were not reversed by the miR-124-3p mimic, but the miR-124-3p inhibitor reversed these changes. MiR-124-3p may help reduce type 2 inflammation in AR by regulating IL-4R-u03b1 signaling, and miR-124-3p could be a promising new AR treatment target.

Source link: https://doi.org/10.1007/s00011-022-01614-x


Clinical study on the treatment of moderate to severe persistent allergic rhinitis by posterior nasal nerve combined with anterior ethmoid neurotomy

Objectives: To investigate the clinical effects of posterior nasal nerve stimulation and anterior ethmoid neurotomy in the treatment of moderate to severe persistent allergic rhinitis. Methods: Patients with moderate to severe persistent allergic rhinitis were admitted to Linhai Second People's Hospital from August 2019 to June 2020 as subjects for prospective research and design. All patients underwent posterior nasal neurotomy and anterior ethmoid neurotomy simultaneously, with posterior nasal neurotomy and anterior ethmoid neurotomy. With a statistically significant difference, one year postoperatively was lower than that preoperatively; with quality of life, nasal symptoms, occupational difficulties, sleep disorders, emotional disorders, and other signs, there was no difference between one year postoperatively and those preoperatively; The study of a clinical research into the treatment of moderate to severe persistent allergic rhinitis by the posterior nasal nerve and anterior ethmoid neurotomy.

Source link: https://doi.org/10.12669/pjms.38.7.5561


Allergic rhinitis

Allergic rhinitis affects more than 20% of the population of Westernized countries and has a major effect on quality of life and school/work results. Pathogenesis involves the induction of type 2 lymphocyte production and tissue eosinophilia. Immediate symptoms result from allergen cross-linking adjacent IgE molecules on the surface of mast cells in the nasal mucosa's nasal mucosa, resulting in the release of histamine and tryptase and the production of bradykinin.

Source link: https://doi.org/10.1093/med/9780198746690.003.0409


Clinical Efficacy and Safety of Artesimia annua -Sublingual Immunotherapy in Seasonal Allergic Rhinitis Patients Based on Different Intervention Time

Artemisia is a significant grass pollen in Northern China that can cause several types of common allergic disorders, including allergic rhinitis, conjunctivitis, or asthma. Artemisia Annua Allergens Sublingual Immunotherapy Drops have been proven to be safe and efficient for treating seasonal AR with or without allergic conjunctivitis patients, and they were also available in China. A. annua extracts swath linua extracts as a SLIT group and 43 patients were only treated with symptomatic drugs as a control group, with 43 patients only using symptomatic drugs as a control group. In addition, the SLIT cohort was randomly divided into a 12-13 weeks pre-seasonal care group and 8u20139 weeksu2019 pre-seasonal care group, with each group receiving different durations of SLIT before pollen season. Conclusions: According to monosensitization or polysensitization, A. annua -SLIT can provide equivalent efficacy and safety for SAR patients in the case of undergoing pre-seasonal therapy of 8u20139 or 12 weeks, regardless of monosensitization or polysensitization.

Source link: https://doi.org/10.1159/000524108


Allergic Rhinitis

Allergic rhinitis is the most common atopic disease worldwide, with an increasing incidence worldwide. Although allergic rhinitis is not a fatal disease, it does have a negative effect on the patient's quality of life, which is not limited to disease-specific QOL policies but also general QOL indicators such as the SF36.

Source link: https://doi.org/10.1093/med/9780199918065.003.0018


Allergic rhinitis

Allergic rhinitis affects more than 20% of Westernized countries' population and has a major effect on quality of life and school/work achievement.

Source link: https://doi.org/10.1093/med/9780199204854.003.1806


Evaluation of experimental animal behaviors through establishment of an ovalbumin-induced experimental mouse model of allergic rhinitis

When the immune system responds to environmental allergen exposures, allergic rhinitis became a form of nasal inflammation. Patients with AR can have a variety of sleep and work qualities. The male BALB/c mice were classified as both the Group A and the Group B in this study. BALB/c mice in Group B were sensitized by intraperitoneal injection of ovalbumin on day 0, day 13, and day 20, followed by continuous nasal administration of OVA solution every day between day 21-43. On day 2, day 8, day 13 and day 20, the bactere-buffered saline injection of phosphate-buffered saline perceptible in Group A, received sensitization of intraperitoneal injection of phosphate-buffered saline instead of OVA once a day between day 21 and 43. On the experiment's D29, D30, D36, and D43, results revealed that sneezing times in Group B were much quicker than Group A on the D29, D36, and D43. On the experiment's D29 and D30, the sneezing times in Group A were considerably quicker. On Group B's D29, D30, D36, D43, and D43 of the experiment, the rubbing times were quicker than Group A. On the experiments' D30 and D43, the rubbing times in Group A were noticeably faster. We hope that this RA mouse model will contribute to the development of the novel AR therapeutic drugs and use these novel AR therapeutic drugs to reduce the AR symptoms in AR patients in the future.

Source link: https://doi.org/10.53430/ijbpru.2022.2.1.0030


Study on the mechanism of allergic rhinitis based on the expression of FIB, PCT, hs-CRP, and Th17/Treg-IL10/IL-17 axis balance

Aim : To examine the effect of exogenous interleukin-10 on the expression of FIB, PCT, hs-CRP, and Th17/Treg-IL-17 axis balance in rats with allergic rhinitis' nasal mucosa. 48 female SPF SD rats were randomly divided into three groups: blank control group, AR group, and the IL-10 intervention group. The rats in the control group were treated with normal saline; in the AR group, the rats were given 20 bc L of saline with 50 g of OVA every day; the rats in the control group were treated with 20 u03bc g of OVA. IL-10 administered intraperitoneally to rats in the IL-10 intervention group were intraperitoneally administered with 1 mL of 40 pg/kg IL-10 and OVA. The IL-10 intervention group was made up of mice with AR that had IL-10 in them. By flow cytometry, the presence of Treg and Th17 cells in serum were determined. The AR group's scores of sneezing, nasal itching, and sneezing were all significantly higher than those in the control group, however, the IL-10 intervention group's ratings were lower than those in the AR group. In comparison, the IL-10 group's serum and IL-17 protein levels in the nasal mucosa were lower than those in the AR group, with FIB, PCT, hs-CRP, IgE, and OVAs IgE. In AR rats' nasal mucosa, IL-10 may reduce AR rats' allergy by altering the expression of FIB, PCT, and hs-CRP, as well as the balance of the Th17/Treg-IL-17 axis.

Source link: https://doi.org/10.21203/rs.3.rs-1888856/v1


A Novel Strategy for the Treatment of Allergic Rhinitis: Regulating Treg/Th17 and Th1/Th2 Balance In Vivo by Vitamin D

This prospective study is designed to investigate the role of vitamin D3 in allergic rhinitis and provide theoretical guidance on prevention and treatment of rats from the macroscopic level and investigating the pathological changes of nasal mucosa, Th1 and Th2-related cytokines, and Treg/Th17.

Source link: https://doi.org/10.1155/2022/9249627


The Correlation of Allergic Rhinitis with Obstructive Sleep Apnea Syndrome (OSAS) in Young Adults

Background: Obstructive Sleep Apnea Syndrome is a sleep disorder that can cause breathing difficulties and cause dangerous diseases. Allergic rhinitis can jeopardize sleep patients' sleep quality. Methode: This is an observational study with the aim of determining the relationship between allergic rhinitis patients and the risk of OSAS in young adults. According to a bivariate analysis, allergic rhinitis was strongly linked to the prevalence of OSAS in young adults. Definition: Allergic rhinitis patients with OSAS are 12. 3 times more likely to experience OSAS than non-allergic rhinitis patients with OSAS.

Source link: https://doi.org/10.14710/dimj.v1i1.7930

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions